Sony's (SNE - Get Report) quarterly losses widened from a year earlier and the Japanese electronics giant reduced its earnings outlook for the fiscal year. Sony posted a loss in the April-June quarter of 24.6 billion yen ($316 million) compared with a year-earlier loss of 15.5 billion, hurt by a strong yen and lower sales of LCD TVs. Sales rose 1.4% to 1.52 trillion yen. Sony lowered its outlook for the fiscal year through March 2013 to a profit of 20 billion yen; it projected 30 billion yen back in May.
Bristol-Myers Squibb (BMY - Get Report) suspended a mid-stage study of its experimental hepatitis C drug BMS-094 due to a serious safety issue. The safety issue that forced the company to suspend the phase II study of BMS-094 is believed to be heart failure, according to ISI Group analyst Mark Schoenebaum BMS-094 was the sole reason behind Bristol-Myers' $2.5 billion acquisition of Inhibitex last January. Bristol's Hep C Drug Blow Up May Benefit Gilead, Idenix, Vertex Pharma
Yelp (AAPL) posted Wednesday stronger-than-expected second-quarter revenue. Yelp, which lets users find and review restaurants and other places of interest, reported a loss of 3 cents a share on $32.7 million in revenue, up 67% from last year. . Analysts were expecting a loss of 6 cents a share on sales of $30.5. Yelp noted average monthly unique visitors rose 52% from a year earlier to more than 78 million and active local business accounts jumped 113%. Yelp Screams Higher on Strong Revenue
Earnings are expected Thursday from Kraft Foods (KFT), Kellogg (K), Beam (BEAM), Cardinal Health (CAH), Activision Blizzard (ATVI) and DirecTV (DTV).
-- Written by Joseph Woelfel >To contact the writer of this article, click here: Joseph Woelfel